Giulia Pasello, Martina Lorenzi, Daniela Scattolin, Alessandro Del Conte, Fabiana Cecere, Alberto Pavan, Marianna Macerelli, Valentina Polo, Sara Pilotto, Mariacarmela Santarpia, Enrico Cumerlato, Valentina Da Ros, Giada Targato, Alberto Bortolami, Laura Bonanno, Alessandra Ferro, Alessandro Dal Maso, Stefano Frega, Valentina Guarneri
INTRODUCTION: The observational multicenter prospective FLOWER study (NCT04965701) confirmed effectiveness and safety of osimertinib in the real-world (RW) management of untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) patients. METHODS: Herein, we report updated survival data, post-progression management, cost/effectiveness and budget impact (BI) of osimertinib compared with a RW population receiving gefitinib or erlotinib. RESULTS: Overall, 189 Caucasian patients receiving first-line osimertinib were included...
March 23, 2024: Oncologist